Buscopan® IBS Relief - Product Information Tablets containing hyoscine butylbromide 10mg. Indication: Relief of gastro-intestinal tract spasm associated with medically confirmed irritable bowel syndrome.

Dose: adults (over 12 years) only: initially 1 tablet three times daily, increasing if necessary to 2 tablets four times a day. Contra-indications: myasthenia gravis, megacolon, narrow angle glaucoma, known hypersensitivity to any component.

Warnings and precautions: conditions characterised by tachycardia; those susceptible to intestinal or urinary outlet obstruction; pyrexia. Warn patients to seek medical advice if they develop a painful red eye with loss of vision whilst or after taking Buscopan IBS Relief. Patients with rare hereditary problems of fructose intolerance, glucose-galactose malabsorption or sucrase-isomaltase insufficiency should not take Buscopan IBS Relief since the tablet coat contains sucrose. Advise patients to consult their doctor before taking IBS Relief if: age over 40 years and some time since the last attack of IBS or the symptoms are different; recent rectal bleeding; severe constipation; nausea or vomiting; loss of appetite or weight; difficulty or pain passing urine; fever; recent travel abroad. Advise patients to consult their doctor if they develop new symptoms, or if symptoms worsen, or if they do not improve after 2 weeks of treatment. Interactions: Co-administration with a dopamine antagonist may diminish the effect of both medicines. Undesirable effects: dry mouth, tachycardia, hypersensitivity, skin reactions. Rare: urinary retention; dyshidrosis; isolated cases of anaphylaxis with episodes of dyspnoea and shock.

Pack size and retail price: 20 tablets £4.39 PL 00015/0253 Legal category: GSL Product Licence Holder: Boehringer Ingelheim Ltd., Ellesfield Avenue, Bracknell, Berkshire RG12 8YS. For fuller information please see Summary of Product Characteristics. Prepared in August 2006.